BTIG Maintains Buy on AtriCure, Raises Price Target to $63

Benzinga Newsdesk www.benzinga.com Positive 73.8%

Neg 0% Neu 0% Pos 73.8%

BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.

Comments

No comments yet. Be the first!